Compare Honest Company Inc (HNST) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Sanofi SA — how do they compare? Honest Company Inc trades at $5.07 (market cap $533.20M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 178.5× Honest Company Inc's market cap, and Sanofi SA pays a 6.01% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Sanofi SA for 94 Days on average.
| HNST | SNY | |
|---|---|---|
Market Cap | $533.20M | $95.18B |
Volume | 1,990,155 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $52.34 |
52-Week Low | $2.10 | $39.51 |
Typical Hold Time | 39 Days | 94 Days |
Enterprise Value | $436.81M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, up 2.84% today, but remains in a bearish technical trend. The company shows mixed fundamentals with declining revenue to $371.32M in 2025 and a net loss of -$15.69M, though Q2 2026 earnings beat expectations. Analyst sentiment is cautious with a $5.30 consensus target, while institutional buying from BlackRock and Deutsche Bank provides some support.
The outlook remains challenging with persistent profitability issues and competitive pressures. While strategic exits show early promise and cash flow improved to $14.15M in 2025, investors face risks from margin compression and uncertain growth trajectory. The stock trades at premium valuations despite negative returns, requiring careful risk assessment.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
